 The chemical structures of most protease inhibitors are quite similar, so it is not surprising that some primary mutations lead simultaneously to resistance to multiple protease inhibitors.Cross-resistance is one of the major problems of protease inhibitor treatment.Additional mutations emerging in the protease during continuous protease inhibitor therapy are commonly referred to as secondary mutations.